SARS-CoV-2 virus added to cells. Courtesy of Institute for Molecular Bioscience, University of Queensland
The SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots to COVID-19 patients, University of Queensland researchers have found.
Dr. Emma Gordon and Dr. Larisa Labzin from University of Queensland (UQ)’s Institute for Molecular Bioscience and Dr. Kirsty Short from UQ’s School of Chemistry and Molecular Biosciences pooled their expertise in vascular biology and virology to determine how the virus causes damage to blood vessels.
The researchers found that the cardiovascular complications of COVID-19 are triggered by inflammation caused by infected airway cells.
“At least 40 per cent of patients that are hospitalized with COVID-19 are at high risk of blood clots, and anti-coagulation therapies are now being routinely used,” Gordon said. “There have been many studies attempting to prove whether the virus is infecting cells of the inner blood vessel wall or not. By conducting our experiments using real, infectious virus rather than fragments of the virus’s spike protein, we can definitively say it is not.”
The researchers used UQ’s sophisticated microscopy facilities to track where the virus travelled in the cells and visualize how blood vessels respond to the live virus.
Labzin said the body’s inflammatory response had a big effect on the cardiovascular system because they work together to fight infection – the blood delivers the immune cells to the site of infection and makes blood clots if the blood vessel is damaged.
“When our immune system works well, it clears the virus from our bodies,” Labzin said. “But sometimes it goes into overdrive and we get an overblown inflammatory response causing complications –in the case of COVID-19, this is often blood clots, when there shouldn’t be any. Knowing that it is inflammation causing these cardiovascular complications arising from COVID-19 rather than the virus itself will help us develop the right treatments, and a better understanding of how and why these complications arise.”
This research was published in Clinical and Translational Immunology.
Source: University of Queensland